Immunovant
- Market cap
- 6.62B
- P/E (TTM)i
- -11.40
- P/Bi
- 9.00
- EPSi
- -2.77
- Div yieldi
- 0.00%
- 52W posi
- 53%
Anonymous reader poll. Unscientific, not investment advice.
Immunovant shares were changing hands at 32.04, down 0.22% on the day. At current prices, the business is worth about 6.62B, the #1790 most valuable US-listed company we track. Across 9 analysts the consensus rating is Buy, with an average price target of 50.38 (+57%). Over the past year the stock has ranged from 16.77 to 45.42; it now sits 53% up that band.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 7% of the universe, above its 200-day average.
- Signal has read BUY for 6 months.
- Recent price momentum is +39.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has fallen to 8.4% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 32.11
- Open
- 31.72
- Day range
- 31.58 - 32.75
- Avg price
- 32.25
- Volume
- 1.13M
- Turnover
- 36.48M
- Turnover ratei
- 1.23%
- Volume ratioi
- 0.82
- Amplitudei
- 3.64%
- 52-week rangei
- 16.77 - 45.42
Valuation
- P/Ei
- -11.57
- P/E (TTM)i
- -11.40
- P/Bi
- 9.00
- EPSi
- -2.77
- Book value / shi
- 3.56
- Net profit
- -572.15M
- Net assets
- 735.33M
Share structure
- Market cap
- 6.62B
- Float capi
- 2.94B
- Shares out
- 206.55M
- Float sharesi
- 91.79M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2017-05-10
29.5% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-9.60M net over the window
Short interest
- Shares short
- 17.25M
- % of floati
- 8.35%
- Days to coveri
- 14.34
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Immunovant (IMVT)?
Immunovant last traded at 32.04. The quote on this page refreshes every few seconds while US markets are open.
What is Immunovant's market cap?
About 6.62B.
What is the P/E ratio of Immunovant?
The trailing twelve-month P/E is -11.40. The Valuation tab shows it against the stock's own five-year range.
Does Immunovant pay a dividend?
Immunovant does not currently pay a regular dividend.
Is Immunovant a buy according to analysts?
The consensus of 9 analysts is a Buy rating, with an average 12-month price target of 50.38, which implies 57.2% upside from the current price. This is not investment advice.
What is Immunovant's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Immunovant a B (Buy). Twelve-month momentum in the top 7% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 07:11:09 · For reference only, not investment advice and not tailored to your situation.